Cargando…

Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient

Whether the 2009 pandemic H1N1 influenza vaccine can induce heterosubtypic cross-protective anti-hemagglutinin (HA) neutralizing antibodies is an important issue. We obtained a panel of fully human monoclonal antibodies from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient. Mos...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Weibin, Chen, Aizhong, Miao, Yi, Xia, Shengli, Ling, Zhiyang, Xu, Ke, Wang, Tongyan, Xu, Ying, Cui, Jun, Wu, Hongqiang, Hu, Guiyu, Tian, Lin, Wang, Lingling, Shu, Yuelong, Ma, Xiaowei, Xu, Bianli, Zhang, Jin, Lin, Xiaojun, Bian, Chao, Sun, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111947/
https://www.ncbi.nlm.nih.gov/pubmed/23084424
http://dx.doi.org/10.1016/j.virol.2012.09.034
Descripción
Sumario:Whether the 2009 pandemic H1N1 influenza vaccine can induce heterosubtypic cross-protective anti-hemagglutinin (HA) neutralizing antibodies is an important issue. We obtained a panel of fully human monoclonal antibodies from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient. Most of the monoclonal antibodies targeted the HA protein but not the HA1 fragment. Among the analyzed antibodies, seven mAbs exhibited neutralizing activity against several influenza A viruses of different subtypes. The conserved linear epitope targeted by the neutralizing mAbs (FIEGGWTGMVDGWYGYHH) is part of the fusion peptide on HA2. Our work suggests that a heterosubtypic neutralizing antibody response primarily targeting the HA stem region exists in recipients of the 2009 pandemic H1N1 influenza vaccine. The HA stem region contains various conserved neutralizing epitopes with the fusion peptide as an important one. This work may aid in the design of a universal influenza A virus vaccine.